Historical Information

Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacy SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”), a privately-held, clinical-stage drug discovery

SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has granted Fast Track Development (FTD) status for Cend’s investigational drug, CEND-1, for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma.

Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive partnerships Lisata to combine development

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Patient dosing has begun in a Phase 1b/2a clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1 in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center (KUCC).

SAN DIEGO and JINAN, China, Feb. 16, 2021 (GLOBE NEWSWIRE) --  Cend Therapeutics, Inc. , a clinical-stage biotech company, and  Qilu Pharmaceutical ,  a major Chinese pharmaceutical company, announced today that the companies have entered a Collaboration and License Agreement to develop and

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) --  Cend Therapeutics, Inc. , a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) --  Cend Therapeutics, Inc. , a clinical-stage biotech company, announced the publication of its abstract on the website of the annual meeting of the European Society for Medical Oncology. The poster that includes the detailed results will be presented at

LA JOLLA, Calif., July 08, 2020 (GLOBE NEWSWIRE) --  Cend Therapeutics, Inc.  (formerly DrugCendR, Inc.), a clinical-stage biotech company, announced today changes in the senior management of the company. David Slack, MBA will take over as President and CEO.

LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr. Daniel Von Hoff will be a clinical advisor to the company. In this role, Dr.